- Molecular NameSotalol
- SynonymSotalol HCL
- Weight302.395
- Drugbank_IDDB00489
- ACS_NO3930-20-9
- Show 3D model
- LogP (experiment)0.24
- LogP (predicted, AB/LogP v2.0)0.67
- pka8.2, 9.8
- LogD (pH=7, predicted)-1.73
- Solubility (experiment)5.51 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.47
- LogSw (predicted, AB/LogsW2.0)28.53
- Sw (mg/ml) (predicted, ACD/Labs)1.34
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds8
- TPSA96.04
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug used in individuals with rhythm disturbances (cardiac arrhythmias) of the heart, and to treat hypertension in some individuals.
- Absorption_value95.0
- Absorption (description)In healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.
- Caco_2N/A
- Bioavailability95.0
- Protein binding0.0
- Volume of distribution (VD)1~2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNot metabolised
- Half life10~17 h, increased in renal insufficiency and in elderly subjects.
- ExcretionRenal Lactic (In lactating females)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.
- LD50 (rat)N/A
- LD50 (mouse)N/A